2.01 Selinexor, ECHELON-2, Parachutes, Tumor-Treating Fields, & MedTwitter

Plenary Session

Vinay Prasad, MD MPH

Policy, Medicine, Health, Oncology, Science & Medicine

4.8 • 798 Ratings

🗓️ 12 July 2019

⏱️ 158 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Welcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an interview with Dr. Michael Hayes of Kaiser Permanente on parachutes in medicine plus the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme; and an interview with Dr. Stacie Dusetzina - a leading researcher in health care policy and the cost of cancer drugs, and an avid Twitter user - of Vanderbilt University on #MedTwitter. ECHELON-2: doi.org/10.1016/S0140-6736(18)32984-2 Facing Our Mistakes: doi.org/10.1056/NEJM198401123100211 Parachutes: doi.org/10.9778/cmajo.20170088 TTF: doi.org/10.1016/j.jcpo.2019.100189 Impact of Disclosing Financial Ties: doi.org/10.1001/archinternmed.2010.39 Back us on Patreon! www.patreon.com/plenarysession

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to Plenary Session.
0:04.0	I'm your host, Dr. Vinay Prasad.
0:07.0	I'm a practicing hematologist oncologist
0:09.0	and I'm associate professor of medicine.
0:11.0	I'm interested in issues at the intersection
0:14.0	of medicine, oncology, and health policy,
0:17.0	and that's what you're going to get on this podcast.
0:19.0	Welcome to Season 2.
0:23.5	On this week's episode, we have a few things in store for you.
0:27.0	First, I'm going to talk to you about a new drug approval called Selenexor.
0:31.6	Selenexor is a drug that's made widely available through the U.S. Food and Drug Administration
0:35.9	Accelerated Approval pathway for patients with penta-refractory myeloma. And it's an interesting approval because it puts
0:42.7	the agency's standards to the test, and we're going to run through it this week on plenary session.
0:47.6	Next, I'm joined in plenary session, HQ, via Skype, with Dr. John Renaud. He's going to take us
0:53.5	through a little clinical trial called Echelon 2.
0:56.0	It's a randomized controlled trial testing brintuxemab vidotin in CD30 positive T-cell lymphomas.
1:02.5	You won't want to miss this discussion.
1:04.4	Next, I'm joined in the plenary session HQ studio with Dr. Michael Hayes.
1:09.4	That's right.
1:10.1	You've heard that name on this podcast many times in season one.
1:13.8	Michael Hayes has done some important work with me on parachutes in medicine.
1:17.4	He also recently did a study on the use of TTF or tumor-treating electrical fields for
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.